Boehringer aims to ban sales of generics of empagliflozin in Russia

German family-owned pharma major Boehringer Ingelheim has attracted the Russian antitrust regulator the Federal Anti-Monopoly Service (FAS) in a dispute with the local drugmaker Grotex over the launch of a generic version of its blood sugar-lowering drug Jardiance (empagliflozin) prior to expiration of the original patent, The Pharma Letter’s local correspondent reports.

As of now, the FAS has already announced the initiation of a case against Grotex. The Service will investigate the company for violations of the competition law. According to Boehringer Ingelheim, Grotex introduced a generic version of Jardiance, thereby infringing the empagliflozin’s patent, which does not expire until November 2029.